Search

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

Application forms

The deadline for the EHA Corporate Sponsor application is September 6, 2024, at 13:00 (CEST). Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

Develop yourself

Develop the expertise you need for a successful career in hematology and hematology research! Pick up a new skill or refine an existing skill.

Read more

VIRTUAL: EHA-TSH Hematology Tutorial

June 25&26, 2021

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof H Özsan (Turkish Society of Hematology)
In close collaboration with the Turkish Society of Hematology, EHA has annually organized  live, joint tutorials (nine in the series), which are organized as part of…

Read more

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more